- Home
- OFLX vs GLUE Comparison
OFLX vs GLUE Comparison
Compare OFLX & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFLX
- GLUE
- Stock Information
- Founded
- OFLX 1975
- GLUE 2019
- Country
- OFLX United States
- GLUE United States
- Employees
- OFLX N/A
- GLUE N/A
- Industry
- OFLX Industrial Specialties
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- OFLX Industrials
- GLUE Health Care
- Exchange
- OFLX Nasdaq
- GLUE Nasdaq
- Market Cap
- OFLX 366.4M
- GLUE 351.2M
- IPO Year
- OFLX 2005
- GLUE 2021
- Fundamental
- Price
- OFLX $35.30
- GLUE $4.80
- Analyst Decision
- OFLX
- GLUE Buy
- Analyst Count
- OFLX 0
- GLUE 2
- Target Price
- OFLX N/A
- GLUE $13.50
- AVG Volume (30 Days)
- OFLX 22.3K
- GLUE 369.2K
- Earning Date
- OFLX 10-29-2025
- GLUE 08-07-2025
- Dividend Yield
- OFLX 3.85%
- GLUE N/A
- EPS Growth
- OFLX N/A
- GLUE N/A
- EPS
- OFLX 1.69
- GLUE 0.29
- Revenue
- OFLX $100,700,000.00
- GLUE $177,986,000.00
- Revenue This Year
- OFLX N/A
- GLUE $83.76
- Revenue Next Year
- OFLX N/A
- GLUE N/A
- P/E Ratio
- OFLX $20.93
- GLUE $16.32
- Revenue Growth
- OFLX N/A
- GLUE 2990.57
- 52 Week Low
- OFLX $28.12
- GLUE $3.50
- 52 Week High
- OFLX $57.81
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- OFLX 57.66
- GLUE 51.69
- Support Level
- OFLX $34.25
- GLUE $4.54
- Resistance Level
- OFLX $37.50
- GLUE $4.93
- Average True Range (ATR)
- OFLX 1.08
- GLUE 0.21
- MACD
- OFLX 0.26
- GLUE 0.06
- Stochastic Oscillator
- OFLX 54.73
- GLUE 81.43
About OFLX Omega Flex Inc.
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.